{"title":"Pembrolizumab + EP not cost effective vs EP as first-line treatment for SCLC in the USA","authors":"","doi":"10.1007/s40274-021-08248-9","DOIUrl":"https://doi.org/10.1007/s40274-021-08248-9","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"178 1","pages":"17 - 17"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77718136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TB screening + treatment of young asylum seekers arriving in Germany may be cost effective","authors":"","doi":"10.1007/s40274-021-08262-7","DOIUrl":"https://doi.org/10.1007/s40274-021-08262-7","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"27 1","pages":"31 - 31"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89914281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}